SGLT2 inhibitors versus GLP-1 receptor agonists and risk of kidney replacement therapy and healthcare utilization in bipolar disorder with chronic kidney disease: An active-comparator, new-user cohort study.
Journal of affective disorders · 2026
Abstract e pubblicazione originale
L’abstract è consultabile nella fonte originale. Non viene ripubblicato qui perché non risulta verificata una licenza compatibile.
Leggi nella fonte originale ↗Parole chiave
HumansRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsFemaleRenal Replacement TherapyBipolar DisorderMaleMiddle AgedCohort StudiesAdultPatient Acceptance of Health CareAgedBipolar disorderChronic kidney diseaseGLP-1 receptor agonistsKidney replacement therapySGLT-2 inhibitors
Come citare questo studio
Balwinder Singh, Feyza Yaylaci, Hossam M Ali, Ritika Baweja, Maria L Gonzalez Suarez, Raman Baweja. (2026). SGLT2 inhibitors versus GLP-1 receptor agonists and risk of kidney replacement therapy and healthcare utilization in bipolar disorder with chronic kidney disease: An active-comparator, new-user cohort study.. Journal of affective disorders. DOI: 10.1016/j.jad.2026.122407
Consulta la pubblicazione originale ↗